AbbVie vs Novartis: Strategic Comparison
Direct Answer
AbbVie is slightly larger by revenue, and Novartis is far more profitable. AbbVie reported $61.2 billion of net revenues for 2025, while Novartis reported total revenues of $56.7 billion, including $54.5 billion of net sales. Novartis's net income was $14.0 billion against AbbVie's $4.2 billion, but AbbVie's market value was higher: about $465.3 billion against $275.3 billion on September 29, 2026.
Novartis was formed in Basel in December 1996 by the merger of Ciba-Geigy and Sandoz, and AbbVie became independent of Abbott Laboratories on January 1, 2013. Both now sell more than $50 billion of medicines a year. AbbVie reported $61.2 billion of revenue and $4.2 billion of net income for 2025. Novartis, which reports in US dollars, had total revenues of $56.7 billion, including $54.5 billion of net sales, and $14.0 billion of net income, with about 75,000 full-time equivalent employees against AbbVie's roughly 57,000. AbbVie focuses heavily on immunology (Skyrizi, Rinvoq) and targeted oncology, while Swiss multinational Novartis AG specializes in cardiovascular medicine (Entresto), radioligand cancer therapies (Pluvicto), and innovative targeted neuroscience treatments worldwide.
Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.
Key Differences at a Glance
| Field | AbbVie Inc. | Novartis AG |
|---|---|---|
| Latest annual revenue | $61.2B (FY2025) | $56.7B (FY2025) |
| Founded | 2013 | 1996 |
| Employees | 57,000 | 75,267 |
| Market Cap | $465.8B | $275.3B |
| Headquarters | United States | Switzerland |
| Revenue / Employee | $1.07M / employee | $753k / employee |
| Valuation Multiple | 7.6x P/S | 4.9x P/S |
Strategic Positioning
Business model and competitive context from the cited profiles
AbbVie Inc. Strategic Vector
FY2025 Revenue BaselineAbbVie's corporate roadmap focuses on expanding Skyrizi and Rinvoq into additional autoimmune indications while aggressively replenishing its oncology and neuroscience pipelines through targeted mergers and acquisitions. Led by Chief Executive Officer Robert Michael, AbbVie completed the acquisitions of ImmunoGen for ten billion dollars (adding Elahere, a pioneering antibody-drug conjugate for folate receptor alpha-positive platinum-resistant ovarian cancer) and Cerevel Therapeutics for nearly nine billion dollars (adding emraclidine for schizophrenia and tavapadon for Parkinson's disease). In neuroscience, AbbVie continues to expand Botox Therapeutic and oral CGRP antagonists (Qulipta, Ubrelvy) for migraine management. By pairing cash flow from aesthetics and immunology with next-generation antibody-drug conjugates (ADCs), AbbVie has established a sustainable post-Humira growth trajectory.
Novartis AG Strategic Vector
FY2025 Revenue BaselineNovartis's corporate strategy centers on operating as a pure-play innovative medicines company dedicated to five technology platforms: chemistry, biotherapeutics, xRNA, radioligand therapy, and cell and gene therapy. Under Chief Executive Officer Vas Narasimhan, Novartis completed a multi-year corporate transformation—spinning off Alcon and Sandoz and divesting its stake in Roche for twenty billion dollars—sharpening organizational focus on high-value, high-margin patented medicines. In oncology, Novartis is expanding Pluvicto into earlier-stage prostate cancer while scaling Kisqali's reach in adjuvant early breast cancer (NATALEE trial). Concurrently, Novartis is expanding its radioligand manufacturing footprint in Indiana, New Jersey, and Spain, cementing an unassailable commercial infrastructure for targeted nuclear oncology.
Quick Stats Comparison
| Metric | AbbVie Inc. | Novartis AG |
|---|---|---|
| Revenue | $61.2B (FY2025) | $56.7B (FY2025) |
| Founded | 2013 | 1996 |
| Headquarters | North Chicago, Illinois | Basel, Switzerland |
| Market Cap | $465.8B | $275.3B |
| Employees | 57,000 | 75,267 |
| Revenue / Employee | $1.07M / employee | $753k / employee |
| Valuation Multiple | 7.6x P/S | 4.9x P/S |
AbbVie Revenue vs Novartis Revenue — Year by Year
| Year | AbbVie Inc. | Novartis AG | Higher reported revenue |
|---|---|---|---|
| 2025 | $61.2B | $56.7B | AbbVie Inc. (approx. USD) |
| 2024 | $56.3B | $51.7B | AbbVie Inc. (approx. USD) |
| 2023 | $54.3B | $46.7B | AbbVie Inc. (approx. USD) |
| 2022 | $58.1B | $43.5B | AbbVie Inc. (approx. USD) |
| 2021 | $56.2B | $44.0B | AbbVie Inc. (approx. USD) |
Business Model Breakdown
Overview: AbbVie Inc. vs Novartis AG
This in-depth comparison examines AbbVie Inc. and Novartis AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Novartis AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Novartis AG is widest.
On the headline numbers, annual revenue is $61.2B (FY2025) for AbbVie Inc. and $56.7B (FY2025) for Novartis AG, while their respective market capitalizations stand at $465.8B and $275.3B. AbbVie Inc. is headquartered in United States and Novartis AG in Switzerland, and those different home markets shape how each company competes.
AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics. The company is headquartered in North Chicago, Illinois.
Novartis AG: Novartis is one of the world's largest drugmakers by sales and the larger of Basel's two pharmaceutical groups alongside Roche. Created by the 1996 merger of Ciba-Geigy and Sandoz, it shed eye care (Alcon, 2019) and generics (Sandoz, 2023) and now sells only innovative medicines. Its best-known products include Entresto for heart failure, Cosentyx for psoriasis and arthritis, Kisqali for breast cancer, Kesimpta for multiple sclerosis and Pluvicto for prostate cancer. The company is headquartered in Basel, Switzerland.
Business Models: How AbbVie Inc. and Novartis AG Make Money
AbbVie Inc. and Novartis AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Novartis AG.
AbbVie Inc. business model: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie built its initial commercial empire around Humira (adalimumab)—historically the world's best-selling biologic medicine. Today, AbbVie's business model is anchored by its next-generation immunology franchise: Skyrizi (risankizumab for plaque psoriasis, psoriatic arthritis, and Crohn's disease) and Rinvoq (upadacitinib for rheumatoid arthritis, ulcerative colitis, and atopic dermatitis). Through its landmark sixty-three-billion-dollar acquisition of Allergan, AbbVie operates a lucrative commercial aesthetics and therapeutic franchise led by Botox (Botox Cosmetic and Botox Therapeutic for migraine, spasticity) and the Juvederm dermal filler portfolio, alongside specialized oncology therapeutics like Venclexta and Imbruvica.
Novartis AG business model: Novartis AG is a focused innovative medicines company headquartered in Basel, Switzerland, that discovers, manufactures, and markets transformative therapeutics across four core therapeutic areas: Cardiovascular, Renal and Metabolic (CRM), Immunology, Neuroscience, and Oncology. Following the strategic spin-off of its generic and biosimilar division (Sandoz) and consumer eye-care business (Alcon), Novartis operates as a pure-play, high-margin biopharmaceutical enterprise. Its revenue model is powered by targeted biologics, small molecules, and advanced technology platforms including radioligand therapies (RLTs), cell and gene therapies, and xRNA therapeutics. Flagship blockbusters include Entresto (sacubitril/valsartan for heart failure), Cosentyx (secukinumab for psoriasis and ankylosing spondylitis), Kesimpta (ofatumumab for multiple sclerosis), Pluvicto (radioligand for prostate cancer), and Kisqali (ribociclib for HR+/HER2- breast cancer).
Competitive Advantage: AbbVie Inc. vs Novartis AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Novartis AG.
AbbVie Inc. competitive advantage: AbbVie's durable competitive moat is built upon its world-class commercial execution in immunology, unmatched patent estate design, and the high-margin cash flow engine of the Allergan aesthetics portfolio. When facing the loss of exclusivity for Humira in the United States, AbbVie executed one of the most successful commercial pipeline replacements in biopharma history: developing Skyrizi and Rinvoq with superior clinical efficacy, securing favorable formulary placement with pharmacy benefit managers, and guiding them to combined annual revenues that surpass Humira's peak. In aesthetics, Botox operates with high consumer brand equity and medical practitioner loyalty; because cosmetic neurotoxin injections require physician skill and patient trust, Botox commands extraordinary pricing power and consumer cash-pay insulation from insurance reimbursement cuts.
Novartis AG competitive advantage: Novartis's economic moat is anchored by its pioneering leadership in advanced technology platforms—specifically radioligand therapies and gene therapy manufacturing—and Entresto's entrenched global standard-of-care position in heart failure. In radioligand therapies, Novartis constructed a proprietary global radioisotope supply chain (producing lutetium-177 therapies Pluvicto and Lutathera) that requires specialized nuclear particle accelerators, cyclotrons, and precision short-half-life logistics that generic competitors cannot replicate. In cardiovascular medicine, Entresto is prescribed to millions of heart failure patients worldwide, generating robust multi-billion-dollar cash flows supported by extensive guideline recommendations. Kesimpta provides an easily self-administered targeted B-cell subcutaneous injection for multiple sclerosis, giving Novartis high patient retention in neurology.
Growth Strategy: Where AbbVie Inc. and Novartis AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Novartis AG each plan to expand from here.
AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.
Novartis AG growth strategy: Novartis concentrates on four therapeutic areas and on the US, its largest market. It pairs internal research with bolt-on acquisitions of late-stage or platform biotechs: Chinook (2023, kidney disease), MorphoSys (2024, myelofibrosis), Kate Therapeutics (2024, gene therapy capsids) and Avidity Biosciences (closed February 27, 2026, about $12 billion, neuromuscular RNA medicines). It is also expanding US manufacturing, including radioligand production capacity.
Financial Picture: AbbVie Inc. vs Novartis AG
A closer look at the financial trajectory of AbbVie Inc. and Novartis AG rounds out the comparison.
AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets. AbbVie is a dominant biopharmaceutical company, sustaining a massive market valuation often exceeding $250 billion, heavily driven by its blockbuster immunology and aesthetics portfolios.
Novartis AG: Novartis grew FY2025 net sales 8% to $54.5 billion with a core operating margin above 40% and free cash flow of $17.6 billion. 2026 is a reset year: US generics of Entresto and Promacta cut Q1 2026 net sales 5% at constant currencies to $13.1 billion and core operating income 14%. Q2 2026 net sales rose 1% cc to $14.4 billion with a 41.2% core margin, though net income fell 19%. Management guides for low single-digit sales growth and a low single-digit decline in core operating income for 2026 at constant currencies. Novartis is a Swiss multinational pharmaceutical corporation with a market valuation generally exceeding $200 billion.
Company-Specific SWOT Notes
AbbVie Inc.
Skyrizi generated $17.562 billion and Rinvoq generated $8.304 billion in FY2025 global net revenue, or $25.866 billion combined, after U.S. Humira biosimilar entry.
AbbVie is no longer only an immunology company.
Humira's decline shows the core weakness of the pharmaceutical model: even notable blockbusters eventually lose exclusivity.
Even after diversification, AbbVie's earnings power is tied heavily to Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Humira.
Cerevel adds neuroscience pipeline depth, while ImmunoGen adds Elahere and antibody-drug conjugate expertise.
U.S. drug-pricing pressure remains a major threat.
Novartis AG
Novartis operates an extensive portfolio of patent-protected specialty therapeutics, radioligand therapies, and cardiovascular medicines generating strong recurring revenues.
Proprietary nuclear particle supply chains for Pluvicto and Lutathera establish Novartis as the undisputed pioneer in precision radioligand therapies for metastatic oncology.
Loss of patent exclusivity on legacy blockbuster drugs creates periodic revenue headwind, requiring continuous clinical pipeline replenishment.
Impending patent challenges and generic entry for its multi-billion-dollar heart failure medication Entresto create revenue replacement pressure on the clinical pipeline.
Investing in next-generation radioligand cancer therapies and cell therapies positions Novartis to address unmet oncology medical needs with premium pricing.
Government-mandated drug price negotiation frameworks in the United States and healthcare cost containment policies in Europe pressure pharmaceutical gross margins.
Factual Scorecard
| Category | Result | Why |
|---|---|---|
| Same-period Revenue Scale | AbbVie Inc. | $61.2B (FY2025) versus $56.7B (FY2025); the higher figure is identified after approximate USD conversion. |
| Founded Earlier | Novartis AG | AbbVie Inc. was founded in 2013; Novartis AG was founded in 1996. |
Comparison Takeaway: AbbVie vs Novartis
Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.
Frequently Asked Questions: AbbVie vs Novartis
Is AbbVie bigger than Novartis?
By revenue and market value, yes. AbbVie's 2025 net revenues of $61.2 billion were about 8% higher than Novartis's total revenues of $56.7 billion, and AbbVie was worth about $465.3 billion on September 29, 2026 against Novartis's $275.3 billion. Novartis had more staff, about 75,267 full-time equivalents against about 57,000, and earned much more profit.
Which company makes more profit, AbbVie or Novartis?
Novartis. Its 2025 net income attributable to shareholders was $14.0 billion, and its core operating income was $21.9 billion, a 40.1% core margin. AbbVie's net income was $4.2 billion; its GAAP diluted EPS was $2.36 against adjusted EPS of $10.00, a gap that reflects large acquired R&D and other charges.
What are the top drugs of AbbVie and Novartis?
AbbVie's largest 2025 products were Skyrizi ($17.6 billion), Rinvoq ($8.3 billion) and Humira ($4.5 billion). Novartis's largest were Entresto ($7.7 billion), Cosentyx ($6.7 billion), Kisqali ($4.8 billion) and Kesimpta ($4.4 billion). Skyrizi and Cosentyx both treat psoriasis and psoriatic arthritis.
Who runs AbbVie and Novartis?
Vasant (Vas) Narasimhan has been CEO of Novartis since February 1, 2018, and Giovanni Caforio has chaired its board since March 7, 2025. Robert A. Michael has been AbbVie's CEO since July 2024 and its chairman since July 1, 2025.
Which is better, AbbVie Inc. or Novartis AG?
Neither leads on every measure. AbbVie has the larger revenue ($61.2 billion against $56.7 billion) and the higher market value. Novartis converts far more of its revenue into profit ($14.0 billion of net income against $4.2 billion) and is spread more evenly across oncology, immunology and cardiovascular medicine. Growth was similar in 2025: 8.6% for AbbVie's revenue and 8.4% for Novartis's net sales.
How do Novartis and AbbVie compare in annual revenue?
AbbVie generated $54.3 billion in 2023 worldwide revenue, compared to Novartis's continuing operations revenue of $45.4 billion (excluding the spun-off Sandoz division). Both companies consistently maintain operating profit margins exceeding 30%.
Which company was founded first, AbbVie Inc. or Novartis AG?
Novartis AG was founded in 1996; AbbVie Inc. was founded in 2013.
What revenue did AbbVie Inc. and Novartis AG report?
AbbVie Inc. had $61.2B (FY2025), while Novartis AG had $56.7B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.
How do AbbVie Inc. and Novartis AG make money?
AbbVie Inc.: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Novartis AG: Novartis AG is a focused innovative medicines company headquartered in Basel, Switzerland, that discovers, manufactures, and markets transformative therapeutics across four core therapeutic areas: Cardiovascular, Renal and Metabolic (CRM), Immunology, Neuroscience, and Oncology.
Sources & References
- SEC EDGAR: AbbVie Inc. filings search (10-K, 8-K)
- AbbVie Inc. Corporate Website
- AbbVie Inc. 2025 revenue figure: SEC EDGAR company facts for AbbVie Inc.
- sec.gov
- news.abbvie.com
- investors.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- prnewswire.com
- fda.gov
- cms.gov
- stockanalysis.com
- Novartis AG Corporate Website
- Novartis AG 2025 revenue figure: Novartis AG Form 20-F for fiscal year 2025 (net sales from continuing operations plus other revenues)
- novartis.com
- en.wikipedia.org
- novartis.com
- novartis.com
- stockanalysis.com
- wsj.com
- novartis.com
- novartis.com
- novartis.com
- fiercebiotech.com
Quick Answer
AbbVie is slightly larger by revenue, and Novartis is far more profitable. AbbVie reported $61.2 billion of net revenues for 2025, while Novartis reported total revenues of $56.7 billion, including $54.5 billion of net sales. Novartis's net income was $14.0 billion against AbbVie's $4.2 billion, but AbbVie's market value was higher: about $465.3 billion against $275.3 billion on September 29, 2026.
Verdict
The two run similar-sized businesses with different drug leaders. AbbVie leans on immunology, which produced $30.4 billion, about half of its 2025 revenue, led by Skyrizi and Rinvoq. Novartis is more balanced: oncology brought in $16.8 billion of net sales, immunology $10.3 billion and cardiovascular, renal and metabolism $9.0 billion, led by Entresto ($7.7 billion), Cosentyx ($6.7 billion) and Kisqali ($4.8 billion). Novartis's 2025 net margin was 24.7% against AbbVie's 6.9%, partly because AbbVie booked $5.0 billion of acquired research and milestone expenses.
Cite This Page
Automatically generated citations for researchers.
CorpDigest. (2026). AbbVie Inc. vs Novartis AG Comparison. from https://corpdigest.com/compare/abbvie-vs-novartis
CorpDigest. "AbbVie Inc. vs Novartis AG Comparison." CorpDigest, 2026, https://corpdigest.com/compare/abbvie-vs-novartis.
CorpDigest. "AbbVie Inc. vs Novartis AG Comparison." CorpDigest. 2026. https://corpdigest.com/compare/abbvie-vs-novartis.